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The usual radiologic approach to thrombosed grafts is a
combination of thrombectomy and angioplasty of the
underlying lesion. However, the primary (unassisted) graft
patency after thrombectomy is quite poor. We evaluated
whether graft patency following thrombectomy is improved
by placement of a stent in the stenotic lesion. Using a
prospective, computerized vascular access database, we
identified 14 patients with thrombosed arteriovenous (A-V)
grafts treated with a stent at the venous anastomosis (stent
group). The outcomes of these grafts was compared to those
observed in 34 sex, age-, and date-matched control patients
whose thrombosed A-V grafts were angioplastied (control
group). Both groups were comparable in age, sex, race,
diabetic status, graft age, and number of previous graft
interventions. The immediate technical success, as indicated
by the post-procedure graft to systemic pressure ratio, was
similar in the stent and control groups (0.3370.16 vs
0.4170.17, P¼ 0.14). The primary graft patency (time from
thrombectomy to next intervention) was significantly longer
for the stent group (median survival, 85 vs 27 days, P¼ 0.02).
Assisted or secondary patency (time from thrombectomy to
permanent graft failure) was also longer for the stent group
(median survival, 1215 vs 46 days, P¼ 0.049). In conclusion,
treatment of thrombosed grafts with a stenosis at the venous
anastomosis with a stent results in longer primary and
secondary graft survival, as compared to treatment with
angioplasty. Stent placement may be a useful treatment
modality in a subset of patients with thrombosed A-V grafts
and stenosis at the venous anastomosis.
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Despite K/DOQI guidelines promoting use of arteriovenous
fistulas in preference to grafts for hemodialysis access,1 a
substantial proportion of US hemodialysis patients continue
to use grafts.2,3 The majority of graft failures are due to
thrombosis, which occurs most commonly in the context of
underlying stenosis at the venous anastomosis.4 Salvage of
clotted grafts requires mechanical thrombectomy, in con-
junction with angioplasty of the stenotic lesion. Unfortu-
nately, the long-term success rate of this approach is quite
poor, and the primary (intervention-free patency) following
graft thrombectomy is only 30–63% at 3 months and 11–34%
at 6 months.5–10
Stent placement has been introduced for treatment of
grafts in which angioplasty results in suboptimal technical
success or if the stenosis recurs rapidly. A number of small
series have reported the outcomes of stent placement for
vascular access with refractory stenosis.11–17 Unfortunately,
these studies have suffered from several methodologic
limitations, including retrospective data collection, absence
of a suitable control group, combining patent and throm-
bosed grafts, combining stents placed at a variety of stenotic
sites, and combining grafts with fistulas. A recent uncon-
trolled study suggested that stents may improve the patency
following graft thrombectomy in selected patients.11
To address these limitations, we have evaluated the
outcomes of thrombosed grafts treated with thrombectomy
and stent placement at the venous anastomosis. We
compared the outcomes to those observed in age-, sex-,
and time-matched control patients with clotted grafts and
stenosis at the venous anastomosis treated with mechanical
thrombectomy and angioplasty.
RESULTS
The clinical characteristics of the patients treated with stent
and the age-, sex-, and time-matched controls are compared
in Table 1. The two treatment groups did not differ
significantly in age, sex, race, diabetic status, or frequency
of hypertension or coronary artery disease. Moreover, the
graft age, number of previous graft interventions, and
number of previous vascular accesses were similar between
the two treatment groups.
To assess the technical success of the intervention, we
measured the intra-graft and systemic blood pressures upon
completion of the procedure. The intra-graft to systemic
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pressure ratio was not significantly different between patients
treated with stents and those receiving conventional angio-
plasty (0.3370.16 vs 0.4170.17, P¼ 0.14).
Unassisted or primary graft patency (time from initial
placement to next intervention) was significantly longer for
the stent group, with a median survival of 85 vs 27 days,
P¼ 0.02 (Figure 1). The primary patency was 76 vs 48% at 30
days, 48 vs 24% at 90 days, and 19 vs 3% at 180 days. Assisted
or secondary graft patency (time from initial placement to
permanent graft failure) was also longer for the stent group,
with a median survival of 1215 vs 46 days, P¼ 0.049
(Figure 2). The secondary patency was 76 vs 62% at 30 days,
76 vs 42% at 90 days, and 57 vs 38% at 180 days.
DISCUSSION
The majority of arteriovenous (A-V) grafts fail because of
thrombosis.4,18 Unassisted graft survival after thrombectomy
and angioplasty is significantly worse than that obtained
following elective angioplasty of patent grafts. A comparison
of graft outcomes after radiologic interventions at our
institution found that the primary patency was only 30% at
3 months for clotted grafts, as compared with 71% for patent
grafts undergoing elective angioplasty.7 Not surprisingly,
graft survival was worse if there was a residual stenosis after
the angioplasty. However, even in the subset of patients with
no residual stenosis after the intervention, the primary
3-month patency was still lower in clotted grafts as compared
with patent grafts undergoing elective angioplasty (median
survival, 2.5 vs 6.9 months). Modification of the radiologic
approach to clotted grafts may improve their survival
following the intervention.
Graft stenosis occurs as a consequence of aggressive
myointimal hyperplasia, which occurs most commonly at the
venous anastomosis.19 Vascular injury resulting from the
angioplasty may actually accelerate the process of myointimal
hyperplasia, thereby resulting in early restenosis.20 Endolum-
inal stents, by forming a rigid scaffold at the venous
anastomosis, may slow the encroachment of the area of
myointimal hyperplasia into the vascular lumen, thereby
limiting the magnitude of recurrent stenosis. Thus, use of
stents may be of utility in preventing restenosis following
angioplasty. A small randomized study comparing stents with
conventional angioplasty found no difference in primary
graft patency following the intervention.15 However, this
study enrolled a mixture of clotted grafts and patent grafts,
and the stenotic lesions were at a variety of locations, limiting
the interpretation of the findings. A recent study reported the
outcomes of clotted grafts undergoing thrombectomy, as well
as stent placement at the venous anastomosis.11 In this more
homogeneous group of grafts, the primary graft patency was
63% at 6 months. Although there was no matched control
group treated with angioplasty alone, the unassisted graft
survival was far superior to that reported in several series
(11–34% at 6 months).5–10
The present study extends these observations by providing
a comparison of the outcomes of clotted grafts undergoing
thrombectomy and stent placement at the venous anasto-
mosis with matched control patients treated with throm-
bectomy and angioplasty. Clotted grafts treated with stents
had significantly longer primary and secondary patencies
than those treated with conventional angioplasty (Figures 1
and 2). The use of a concurrent, matched control group is
important, because several clinical factors have been
associated with differences in graft outcomes following
angioplasty. For example, the primary patency is shorter in
women than men,21 and shorter if the stenosis is at a
peripheral site, as compared with a central vein.12 Both
factors were similar between the stent and control group in
the present investigation. The superior graft patency with
stent placement is particularly striking, given that the control
Table 1 | Baseline characteristics of the study patients
Feature Stent Control P-value
Number of patients 14 34
Age (years) 53717 58713 0.24
Sex, female (N (%)) 10 (72) 21 (62) 0.52
Race, black (N (%)) 13 (93) 29 (85) 0.47
Diabetes (N (%)) 5 (36) 15 (44) 0.59
HTN (N (%)) 12 (86) 30 (88) 0.81
CAD (N (%)) 4 (28) 10 (29) 0.95
Graft age (days) 2967253 5137478 0.12
# prev interv 2.071.8 1.772.2 0.66
# prev acc 1.471.3 1.671.3 0.57
CAD, coronary artery disease; HTN, hypertension; # prev interv, number of previous
interventions in the present graft; # prev acc, number of previous vascular accesses
(fistula or graft).
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Figure 1 | Primary patency of thrombosed A-V grafts treated with
stent after angioplasty (solid line) and control patients (dashed
line). P¼ 0.02 by the log-rank test.
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Figure 2 | Secondary patency of thrombosed A-V grafts treated
with stent after angioplasty (solid line) and control patients
(dashed line). P¼ 0.049 by the log-rank test.
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group appeared to have good technical results after
angioplasty alone.
A number of randomized studies evaluating the efficacy
of access surveillance on graft outcomes have found
that surveillance is an excellent tool for identifying hemo-
dynamically significant graft stenosis. However, the higher
frequency of pre-emptive angioplasty in the surveillance
group does not appear to translate into a reduction in graft
thrombosis or prolongation of graft survival.22–25 This
discrepancy suggests that angioplasty may not be effective
in producing sustained improvement of the stenotic lesion.
Stent deployment may improve the durability of graft
angioplasty and decrease the variability between operators
in graft patency following radiologic interventions. Thus, it is
possible that more frequent use of stents might enhance the
value of graft surveillance.
There are a number of stent types available on the market,
but no clinical trials comparing graft outcomes between stent
types. It is also possible that administration of anti-platelet
agents after stent placement or employment of drug-eluting
stents may further improve the primary patency of grafts
following thrombectomy. The routine use of clopidogrel after
stent placement in the series reported by Sreenarasimhaiah
et al.11 may explain the higher 6-month primary patency as
compared with the present study (63 vs 19%). Of course,
myointimal hyperplasia can still occur at sites other than the
venous anastomosis, thereby contributing to recurrent graft
failure.
In summary, our results suggest that in thrombosed grafts
with a stenosis at the venous anastomosis, treatment with a
stent may result in longer primary and secondary graft
survival as compared to treatment with angioplasty. Stent
placement may be a useful treatment modality in a subset of
patients with thrombosed A-V grafts and stenosis at the
venous anastomosis. Because employment of stents adds
substantially to the cost of treating clotted grafts (B$1000), a
multicenter randomized study is warranted to evaluate the
efficacy and cost-effectiveness of this approach in prolonging
the primary patency of these grafts. Such a study could also
define the specific subsets of patients with clotted grafts who
are likely to benefit from stent use.
MATERIALS AND METHODS
Study population
The University of Alabama at Birmingham provides medical care for
approximately 450 hemodialysis patients, under the supervision of
12 full-time nephrologists. Two full-time access coordinators hired
by the Division of Nephrology schedule all access procedures, and
maintain a prospective, computerized database of all vascular access
procedures.26 All endovascular procedures are carried out in the
interventional radiology suite by either an interventional nephro-
logist or an interventional radiologist.
Procedures
All patients diagnosed with a thrombosed graft underwent
mechanical thrombectomy within 48 h of diagnosis, in conjunction
with angioplasty of the underlying stenotic lesion. The grafts were
initially accessed with a single needle at the arterial limb of the graft.
A glide wire was passed up to the central vessels and the needle
exchanged for a 6-French catheter sheath. Mechanical thrombect-
omy was achieved with a Trerotola device. A second 6-French sheath
was placed in the venous limb of the graft, and a glide wire passed
into the arterial circulation. A Fogarty balloon was passed through
the wire beyond the arterial anastomosis and pulled back to dislodge
the clot. An antegrade and retrograde angiogram of the graft was
performed to assess patency and look for stenotic lesions. An
angioplasty balloon (Conquest, Bard Inc., Murray Hill, NJ, USA)
was placed and inflated at the level of the stenotic site.
If severe elastic recoil or significant residual stenosis was
observed, or if the stenosis had recurred shortly after a previous
intervention, a stent was deployed at the stenotic site. Different types
of stents were used, including SMART, Wallstent, Prote´ge´, and
Fluency. Their sizes varied from 7 to 9 mm in diameter and 20 to
40 mm in length. All patients received 3000–4000 U heparin during
the procedure.
Upon completion of the procedure, intra-graft and systemic
blood pressures were measured. We have previously shown that the
intra-graft to systemic pressure ratio was predictive of primary
(intervention-free) graft patency.7,21 None of the patients treated
with an endoluminal stent were treated with an anti-platelet agent
after the intervention.
Data analysis
The prospective computerized database was used to identify all 887
mechanical graft thrombectomy procedures performed during the
6-year period from 1 April 1999 to 31 March 2005. Of the total, 20
were treated with an endoluminal stent: 13 because of poor technical
result after angioplasty, one because of rapid elastic recoil, five
because of rapid restenosis after the previous graft intervention, and
one because of vascular dissection following the angioplasty. There
were no technical complications related to stent placement. The site
of stenosis was at the venous anastomosis in 14 patients, the
brachiocephalic vein in four, and the peripheral draining vein in
two. Because the primary patency may vary by the location of
stenosis,12 we limited the outcome analysis to the 14 grafts with a
stenosis at the venous anastomosis.
For comparison, we selected 34 age-, sex-, and time-matched
control patients with thrombosed grafts and a stenosis at the venous
anastomosis treated with thrombectomy and conventional angio-
plasty. Using the computerized database, we initially identified for
each index patient receiving a stent, all patients undergoing graft
thrombectomy in the time period spanning 15 days before the index
case to 15 days following the index case. From this list, we selected
the two same-sex patients closest in age to the stent patient. Finally,
we excluded those patients who did not have a significant stenosis at
the venous anastomosis. Permission was obtained from the
University of Alabama at Birmingham Institutional Review Board
to review each patient’s medical records for research purposes.
Demographic and clinical information collected included patient
age, sex, race, and comorbidity. The access database was analyzed to
determine the date of first intervention (angioplasty, thrombectomy,
or surgical revision) subsequent to thrombectomy. Primary
(unassisted) patency was calculated from the date of initial
thrombectomy to the first subsequent graft intervention. Secondary
(assisted patency) was calculated from the date of initial throm-
bectomy to permanent graft failure, regardless of the number of
interventions. Graft follow-up was censored for patient death,
change of dialysis modality, or transfer to an outside dialysis facility.
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Statistical analysis
Baseline patient characteristics were compared between both groups
using Student’s t-tests or w2 analysis. Survival curves for primary and
secondary graft patency were generated using Kaplan–Meier
methodology, and the differences between groups were analyzed
by the log-rank test.
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